• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

透析患者钙磷代谢紊乱的临床管理

Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients.

作者信息

Eddington Helen, Heaf James G

机构信息

Salford Royal NHS Foundation Trust, Manchester , UK.

Department of Nephrology B, Herlev Hospital , University of Copenhagen , Denmark.

出版信息

NDT Plus. 2009 Aug;2(4):267-72. doi: 10.1093/ndtplus/sfp044. Epub 2009 Apr 28.

DOI:10.1093/ndtplus/sfp044
PMID:25984012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4421242/
Abstract

Management of chronic kidney disease-mineral bone disorder can be difficult in renal patients. This review aims to explain why the control of disturbed calcium, phosphate, parathyroid hormone and vitamin D metabolism is important in dialysis patients. The methods available to regulate these parameters include diet, phosphate binders, dialysate calcium, native vitamin D, active vitamin D derivatives and calcimimetics. An overview of current treatment guidelines will be discussed.

摘要

慢性肾脏病-矿物质和骨异常在肾病患者中的管理可能具有挑战性。本综述旨在解释为何控制钙、磷、甲状旁腺激素及维生素D代谢紊乱对透析患者很重要。调节这些参数的可用方法包括饮食、磷结合剂、透析液钙、天然维生素D、活性维生素D衍生物及拟钙剂。将讨论当前治疗指南的概述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae0/4421242/1e5d73d437af/sfp044fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae0/4421242/1e5d73d437af/sfp044fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ae0/4421242/1e5d73d437af/sfp044fig1.jpg

相似文献

1
Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients.透析患者钙磷代谢紊乱的临床管理
NDT Plus. 2009 Aug;2(4):267-72. doi: 10.1093/ndtplus/sfp044. Epub 2009 Apr 28.
2
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病（未透析）患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
3
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
4
[Dynamic changes in calcium and phosphate plasma concentrations in the patients on peritoneal dialysis].[腹膜透析患者血浆钙和磷浓度的动态变化]
Vojnosanit Pregl. 2006 Jan;63(1):27-30. doi: 10.2298/vsp0601027j.
5
Bone health and vascular calcification relationships in chronic kidney disease.慢性肾脏病中骨骼健康与血管钙化的关系
Int Urol Nephrol. 2007;39(4):1209-16. doi: 10.1007/s11255-007-9276-9. Epub 2007 Sep 26.
6
Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.慢性肾功能不全时钙磷代谢紊乱的管理，重点在于控制高磷血症。
Nephrol Dial Transplant. 2002 May;17(5):723-31. doi: 10.1093/ndt/17.5.723.
7
Challenges in the therapy of secondary hyperparathyroidism.继发性甲状旁腺功能亢进治疗中的挑战。
Ther Apher Dial. 2005 Feb;9(1):4-8. doi: 10.1111/j.1774-9987.2005.00208.x.
8
[Renal osteodystrophy (3); its treatment in dialysis patients].[肾性骨营养不良（3）；透析患者的治疗]
Nephrologie. 2000;21(8):413-24.
9
[Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].[慢性肾脏病与骨骼。腹膜透析患者慢性肾脏病-矿物质和骨异常的管理]
Clin Calcium. 2009 Apr;19(4):508-13.
10
How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?拟钙剂在透析患者甲状旁腺激素、钙和磷紊乱的管理中如何发挥作用？
Semin Dial. 2005 May-Jun;18(3):226-38. doi: 10.1111/j.1525-139X.2005.18318.x.

引用本文的文献

1
Prevalence of Impaired Physical Mobility in Dialysis Patients: A Single-Centre Cross-Sectional Study.透析患者身体活动能力受损的患病率：一项单中心横断面研究。
J Clin Med. 2023 Oct 20;12(20):6634. doi: 10.3390/jcm12206634.
2
Skin Cutibacterium acnes Mediates Fermentation to Suppress the Calcium Phosphate-Induced Itching: A Butyric Acid Derivative with Potential for Uremic Pruritus.皮肤痤疮丙酸杆菌介导发酵以抑制磷酸钙诱导的瘙痒：一种具有治疗尿毒症瘙痒潜力的丁酸衍生物。
J Clin Med. 2020 Jan 22;9(2):312. doi: 10.3390/jcm9020312.
3
IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.

本文引用的文献

1
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.联合补充钙和维生素D3对中度慢性肾脏病患者血清全段甲状旁腺激素的影响
Am J Kidney Dis. 2009 Mar;53(3):408-16. doi: 10.1053/j.ajkd.2008.09.020. Epub 2009 Jan 29.
2
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.一项随机、双盲、安慰剂对照研究，旨在评估盐酸西那卡塞在未接受透析的慢性肾脏病参与者中的疗效和安全性。
Am J Kidney Dis. 2009 Feb;53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24.
3
Vitamin D status of chronic kidney disease patients living in a sunny country.
IL-6/p-BTK/p-ERK 信号转导介导磷酸钙诱导的瘙痒。
FASEB J. 2019 Nov;33(11):12036-12046. doi: 10.1096/fj.201900016RR. Epub 2019 Jul 31.
生活在阳光充足国家的慢性肾病患者的维生素D状况。
J Ren Nutr. 2008 Sep;18(5):408-14. doi: 10.1053/j.jrn.2008.05.004.
4
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.成纤维细胞生长因子23与接受血液透析患者的死亡率
N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.
5
Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization.磷酸钙晶体可诱导人血管平滑肌细胞死亡：动脉粥样硬化斑块不稳定的一种潜在机制。
Circ Res. 2008 Aug 29;103(5):e28-34. doi: 10.1161/CIRCRESAHA.108.181305. Epub 2008 Jul 31.
6
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.碳酸镧的长期疗效和安全性概况：长达6年的治疗结果
Nephron Clin Pract. 2008;110(1):c15-23. doi: 10.1159/000149239. Epub 2008 Jul 31.
7
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.高剂量碳酸镧可在减少片剂服用量的情况下控制血清磷水平，受到患者和医生的青睐：一项多中心研究。
Clin J Am Soc Nephrol. 2008 Sep;3(5):1437-45. doi: 10.2215/CJN.04741107. Epub 2008 Jun 25.
8
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.一项为期1年的随机试验，比较醋酸钙与司维拉姆对脂质控制相当的血液透析患者冠状动脉钙化进展的影响：醋酸钙Renagel评估-2（CARE-2）研究。
Am J Kidney Dis. 2008 Jun;51(6):952-65. doi: 10.1053/j.ajkd.2008.02.298. Epub 2008 Apr 18.
9
The mechanism of phosphorus as a cardiovascular risk factor in CKD.慢性肾脏病中磷作为心血管危险因素的机制。
J Am Soc Nephrol. 2008 Jun;19(6):1092-105. doi: 10.1681/ASN.2007070760. Epub 2008 Apr 16.
10
A bimodal association of vitamin D levels and vascular disease in children on dialysis.接受透析治疗儿童的维生素D水平与血管疾病的双峰关联。
J Am Soc Nephrol. 2008 Jun;19(6):1239-46. doi: 10.1681/ASN.2007090993. Epub 2008 Mar 12.